查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球奈米生物技术市场：按类型、疗法、技术、应用、最终用户、地区、机会、预测，2017-2031
市场调查报告书
商品编码
1422075

全球奈米生物技术市场：按类型、疗法、技术、应用、最终用户、地区、机会、预测，2017-2031

Nanobiotechnology Market Assessment, By Type, By Therapeutics, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5个工作天内

价格

2023年全球奈米生物技术市场规模为758亿美元，预计2031年将达到1,431亿美元，2024-2031年预测期间复合年增长率为8.27%。技术进步正在推动全球奈米生物技术市场的成长，扩大研发投资，扩大在医疗保健和医学领域的应用，并增加对个人化医疗和精确药物传输系统的需求。此外，奈米技术和生物技术的融合正在推动诊断、治疗和生物医学研究的进步，为市场扩张做出了重大贡献。

全球奈米生物技术市场的强劲扩张取决于多种重要因素。最重要的是，持续的技术进步正在不断突破创新的界限。奈米科学和工程的突破正在推动奈米生物技术领域新工具和方法的出现，释放出无与伦比的机会。同时，不同领域研发 (R&D) 投资的增加正在推动奈米生物技术的发展。这些重大投资正在推动新应用、材料和研究方法的探索，增加医疗保健和医学领域突破性发现的潜力。奈米技术在医疗保健和医学领域的日益一体化是扩大全球奈米生物技术市场的支柱。

奈米技术在这些领域的适应性将促进诊断学的重大进步，并为早期疾病识别提供敏感和准确的工具。此外，在治疗中，奈米技术可以透过实现标靶和受控药物释放来改变药物传输系统，提高治疗效果，同时最大限度地减少副作用。对个人化医疗和精准给药系统的需求不断增长，进一步推动了全球奈米生物技术市场的成长。奈米技术客製化治疗和介入措施的能力完全符合不断增长的需求，有助于开发适合个人独特基因组成和特定健康状况的治疗方法。此外，奈米技术和生物技术的融合可以充当催化剂，促进诊断、治疗和生物医学研究的突破。这种融合促进了创新，扩大了奈米生物技术的可能性领域，并为全球奈米生物技术市场的扩展和进步做出了重大贡献。

该报告考察了全球奈米生物技术市场，并提供了市场概述，包括按类型、治疗、技术、应用、最终用户、地区以及参与市场的公司概况划分的趋势。

目录

第一章研究方法论

第二章 专案范围与定义

第三章执行摘要

第四章全球奈米生物技术市场展望，2017-2031

  • 市场规模及预测
  • 按类型
  • 依治疗方法
  • 按技术
  • 按用途
  • 按最终用户
  • 按地区
  • 按公司划分的市占率 (%)，2023 年

第 5 章 2017-2031 年全球奈米生物技术市场前景（按地区）

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章 市场测绘，2023 年

第七章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第八章市场动态

第九章 监理架构与创新

第十章 主要与企业状况

第11章价格分析

第十二章案例研究

第十三章 主要公司展望

  • Moderna, Inc.
  • Generation Bio Co.
  • Sanofi S.A.
  • GlaxoSmithKline Plc
  • Arrowhead Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • BlueWillow Biologics, Inc.
  • pSivida Corp.
  • Merck KGaA
  • Starpharma Holdings Ltd.
  • Thermo Fisher Scientific Inc.

第十四章 战略建议

第十五章 查询及免责声明

Product Code: MX10940

Global nanobiotechnology market size was valued at USD 75.8 billion in 2023, expected to reach USD 143.1 billion in 2031, with a CAGR of 8.27% for the forecast period between 2024 and 2031F. Technological advancements propel the growth of the global nanobiotechnology market, amplify R&D investments, expand uses in healthcare and medicine, and increase the need for personalized medicine and precise drug delivery systems. Moreover, the merging of nanotechnology and biotechnology has sparked advancements in diagnostics, therapeutics, and biomedical research, contributing significantly to market expansion.

The robust expansion of the global nanobiotechnology market relies on various pivotal factors. Foremost, the ongoing progression of technological advancements continually pushes the boundaries of innovation. Nanoscale science and engineering breakthroughs have unlocked unparalleled opportunities, fostering the emergence of fresh tools and methodologies in the domain of nanobiotechnology. Concurrently, heightened investments in research and development (R&D) across diverse sectors have propelled the evolution of nanobiotechnology. These substantial investments drive explorations into novel applications, materials, and methodologies, amplifying the potential for groundbreaking discoveries in healthcare and medicine. The increasing integration of nanotechnology in healthcare and medicine serves as a linchpin for expanding the global nanobiotechnology market.

Nanotechnology's adaptability in these arenas facilitates notable strides in diagnostics, presenting highly sensitive and precise tools for early disease identification. Additionally, in therapeutics, nanobiotechnology transforms drug delivery systems by enabling targeted and controlled medication release, improving treatment effectiveness while minimizing adverse effects. The rising demand for tailored medicine and precise drug delivery systems further propels the growth of global nanobiotechnology market. Nanotechnology's ability to customize treatments and interventions aligns perfectly with the escalating need, fostering the development of therapies personalized to an individual's distinct genetic composition or specific health conditions. Moreover, the convergence of nanotechnology and biotechnology acts as a catalyst, driving breakthroughs in diagnostics, therapeutics, and biomedical research. This fusion fuel innovation, expanding the realm of possibilities in nanobiotechnology and significantly contributing to the expansion and progression of global nanobiotechnology market.

Expanding Uses in Healthcare and Medicine

The increasing incorporation of nanotechnology in healthcare and medicine is a fundamental catalyst for the growing global nanobiotechnology market. Nanotechnology's application in these domains encompasses diverse advancements, particularly in diagnostics, therapeutics, and biomedical research. In diagnostics, nanomaterials facilitate the development of exceptionally sensitive and precise diagnostic instruments, enabling early disease detection with outstanding accuracy. Nanobiotechnology transforms drug delivery systems regarding therapeutics, heightening effectiveness while reducing side effects through targeted and precise release of medicinal compounds. Moreover, nanoscale materials drive the innovation of novel treatments, encompassing nano-formulations for various illnesses, gene therapy, and advancements in regenerative medicine. The fusion of nanotechnology and biotechnology has spurred breakthroughs in biomedical research, fostering sophisticated tools to examine biological systems at a molecular level. These strides facilitate the creation of pioneering medical solutions, propelling the global nanobiotechnology market by promising to reshape healthcare delivery and improve outcomes on a global scale.

Amplified Research and Development Investments

Augmented research and development funding significantly drives the global nanobiotechnology market forward. These increased investments stimulate innovative research, nurturing progress in nanoscale technologies, materials, and approaches. They spark pivotal advancements in healthcare, leading to the development of accurate diagnostic tools, specialized drug delivery systems, and tailored treatments. Through the amplification of R&D funding, the market gains from heightened innovation, expanding the frontiers of nanobiotechnology to provide groundbreaking solutions for healthcare, medicine, and biomedical research worldwide.

For instance, in July 2023, McGill University stated that it had agreements in place to fund two innovative research projects involving lipid nanoparticles (LNPs) with Moderna, Inc., a biotechnology company that is leading the way in messenger RNA (mRNA) therapies and vaccines. Since LNPs are the main means of delivering mRNA strands to the target cells, they play a crucial role in mRNA therapeutics like vaccinations.

Government Initiatives

Governments globally are proactively executing diverse strategies to drive the advancement of the global nanobiotechnology market. These initiatives involve significant financial commitments directed towards research and development, stimulating progress in nanoscale technologies. Furthermore, governments institute favorable policies, frameworks, and partnerships to propel nanobiotechnology forward. They foster collaborations between academia, industry, and research entities, fostering knowledge sharing and hastening market expansion. Additionally, governments allocate resources towards infrastructure and offer incentives, aiming to promote the uptake and commercial viability of nanobiotechnology. The concerted effort supports its broad-ranging implementation across sectors like healthcare, medicine, agriculture, and environmental sustainability.

For instance, the National Nanotechnology Initiative (NNI) in the United States was requested to receive USD 1.99 billion in the President's 2023 Budget in February 2023. Since the NNI's founding in 2001, the total requested, including the 2023 request, has exceeded USD 40.7 billion. The National Nanotechnology Initiative (NNI) is a research and development (R&D) program of the United States government. In addition to supporting a shared infrastructure, enabling resource leveraging without duplication, and establishing shared goals, priorities, and strategies that support agency-specific missions and activities, the NNI improves interagency coordination of nanoscale R&D.

Use of Nanotechnology in Drug Delivery

The rising need for nanotechnology in delivering drugs serves as a key catalyst driving the growth of global nanobiotechnology market. Nanotechnology's role in drug delivery allows for precise, targeted drug application, improving effectiveness while reducing potential side effects. The growing demand arises from nanoscale materials' ability to encapsulate medications, ensure their safe delivery to precise cells or tissues. Additionally, nanotechnology enables controlled release methods, improving therapeutic results. The increasing dependence on nanotechnology in drug delivery underscores its importance, fostering advancements and growth in the nanobiotechnology market, reshaping medication administration for better healthcare outcomes worldwide. To speed up the development of nucleic acid-based medicines and vaccines, Mana.bio, a biotechnology startup that accelerates programmable drug delivery, for instance, announced its AI-based lipid nanoparticle (LNP) delivery platform in October 2023, underwritten by a USD 19.5 million oversubscribed seed rounds. With the funding, Mana.bio may continue developing its unique, specially designed AI LNP platform, which could potentially lead to the creation of novel treatments for a variety of unmet needs by delivering RNA and gene therapies to extrahepatic tissues in the body in a safer and more efficient manner.

Growing Popularity of Nanoparticles

The increasing requirement for nanoparticles acts as a substantial driving factor in advancing the global nanobiotechnology market. These tiny entities hold a central position across diverse fields, notably in healthcare, medicine, and materials science. Their distinct characteristics facilitate precise drug administration, improving treatment effectiveness while reducing adverse effects. Moreover, nanoparticles find utility in diagnostics, imaging, and various industrial domains. The rising interest in these adaptable particles emphasizes their significance in propelling nanobiotechnology, encouraging breakthroughs that transform healthcare methodologies, advanced material development, and a broad range of industrial applications, thereby impacting the market's growth and development. A benchtop instrument for detailed analysis of lipid nanoparticles and other nano-formulations, for example, is scheduled to be launched in September 2023 by SPARTA Biodiscovery, a spin-out company from Imperial College London. According to Jelle Penders, PhD, co-inventor of Single Particle Automated Raman Trapping Analysis (SPARTA), the instrument is the first to simultaneously identify the composition and size of nano-formulations in an automated and label-free manner.

Future Market Scenario

The global nanobiotechnology market's future holds remarkable promise, driven by ongoing innovations and evolving applications. Nanobiotechnology leads the forefront of scientific advancement, offering revolutionary changes across numerous industries. In healthcare, it facilitates precise drug delivery, personalized medicine, and advanced diagnostics, improving treatments with reduced side effects. Its impact spans environmental remediation, agriculture, electronics, and energy sectors, revolutionizing material science and manufacturing processes. Continual research and development efforts, along with increased global investments, drive market expansion. Advancing technology and interdisciplinary collaborations further unlock nanobiotechnology's potential, addressing previously insurmountable challenges. Moreover, the convergence of nanotechnology, biotechnology, and information technology foretells a new era, where nanobiotechnology becomes pivotal in addressing global health, environmental, and societal concerns. The trajectory signifies a promising and transformative path for the global nanobiotechnology market.

Key Players Landscape and Outlook

Key players in the global nanobiotechnology market proactively participate in collaborative endeavors encompassing strategic alliances, joint research initiatives, and shared investments. Their goal is to collectively leverage resources, expertise, and technological advancements, driving innovation and broadening the horizons of nanobiotechnology applications. These collaborative initiatives allow for the harnessing of complementary strengths, enabling the creation of innovative products and solutions. Furthermore, these partnerships facilitate market exploration across diverse industries and consumer segments, fostering the widespread adoption of nanobiotechnology. It amplifies its influence not only in healthcare, materials science, and environmental sustainability but also in various other domains.

In March 2023, for example, Moderna announced that it had applied for Generation Bio's exclusive stealth cell-targeted lipid nanoparticle (ctLNP) delivery system to find and create non-viral genetic medicines for liver and immune system disorders. This partnership could bring in up to $1.876 billion for Generation Bio. Moderna has obtained the option to license the closed-end DNA (ceDNA) novel build technology from Generation Bio as well as ctLNP.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Nanobiotechnology Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Type
    • 4.2.1. 0-10 Nm
    • 4.2.2. 10-100 Nm
  • 4.3. By Therapeutics
    • 4.3.1. Dental Therapies
    • 4.3.2. Cardiac Therapies
    • 4.3.3. Orthopedic Therapies
    • 4.3.4. Others
  • 4.4. By Technology
    • 4.4.1. Nanocrystals
    • 4.4.2. Nanoparticles
    • 4.4.3. Liposomes
    • 4.4.4. Micelles
    • 4.4.5. Nanotubes
    • 4.4.6. Others
  • 4.5. By Application
    • 4.5.1. Therapeutics
    • 4.5.2. Nano diagnostics
    • 4.5.3. Tissue Engineering
    • 4.5.4. Gene Therapy
    • 4.5.5. Molecular Nanotechnology
    • 4.5.6. Drug Delivery
    • 4.5.7. Food Safety
  • 4.6. By End-user
    • 4.6.1. Pharmaceutical Companies
    • 4.6.2. Research Institutes and Laboratories
    • 4.6.3. Academic Institutions
    • 4.6.4. Others
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. South America
    • 4.7.4. Asia-Pacific
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Nanobiotechnology Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Type
      • 5.1.2.1. 0-10 Nm
      • 5.1.2.2. 10-100 Nm
    • 5.1.3. By Therapeutics
      • 5.1.3.1. Dental Therapies
      • 5.1.3.2. Cardiac Therapies
      • 5.1.3.3. Orthopedic Therapies
      • 5.1.3.4. Others
    • 5.1.4. By Technology
      • 5.1.4.1. Nanocrystals
      • 5.1.4.2. Nanoparticles
      • 5.1.4.3. Liposomes
      • 5.1.4.4. Micelles
      • 5.1.4.5. Nanotubes
      • 5.1.4.6. Others
    • 5.1.5. By Application
      • 5.1.5.1. Therapeutics
      • 5.1.5.2. Nano diagnostics
      • 5.1.5.3. Tissue Engineering
      • 5.1.5.4. Gene Therapy
      • 5.1.5.5. Molecular Nanotechnology
      • 5.1.5.6. Drug Delivery
      • 5.1.5.7. Food Safety
    • 5.1.6. By End-user
      • 5.1.6.1. Pharmaceutical Companies
      • 5.1.6.2. Research Institutes and Laboratories
      • 5.1.6.3. Academic Institutions
      • 5.1.6.4. Others
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. Value
      • 5.1.7.1.2. Volume
      • 5.1.7.2. By Type
      • 5.1.7.2.1. 0-10 Nm
      • 5.1.7.2.2. 10-100 Nm
      • 5.1.7.3. By Therapeutics
      • 5.1.7.3.1. Dental Therapies
      • 5.1.7.3.2. Cardiac Therapies
      • 5.1.7.3.3. Orthopedic Therapies
      • 5.1.7.3.4. Others
      • 5.1.7.4. By Technology
      • 5.1.7.4.1. Nanocrystals
      • 5.1.7.4.2. Nanoparticles
      • 5.1.7.4.3. Liposomes
      • 5.1.7.4.4. Micelles
      • 5.1.7.4.5. Nanotubes
      • 5.1.7.4.6. Others
      • 5.1.7.5. By Application
      • 5.1.7.5.1. Therapeutics
      • 5.1.7.5.2. Nano diagnostics
      • 5.1.7.5.3. Tissue Engineering
      • 5.1.7.5.4. Gene Therapy
      • 5.1.7.5.5. Molecular Nanotechnology
      • 5.1.7.5.6. Drug Delivery
      • 5.1.7.5.7. Food Safety
      • 5.1.7.6. By End-user
      • 5.1.7.6.1. Pharmaceutical Companies
      • 5.1.7.6.2. Research Institutes and Laboratories
      • 5.1.7.6.3. Academic Institutions
      • 5.1.7.6.4. Others
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Therapeutics
  • 6.3. By Technology
  • 6.4. By Application
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Moderna, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Generation Bio Co.
  • 13.3. Sanofi S.A.
  • 13.4. GlaxoSmithKline Plc
  • 13.5. Arrowhead Pharmaceuticals Inc.
  • 13.6. Bristol-Myers Squibb Company
  • 13.7. Merck & Co. Inc.
  • 13.8. BlueWillow Biologics, Inc.
  • 13.9. pSivida Corp.
  • 13.10. Merck KGaA
  • 13.11. Starpharma Holdings Ltd.
  • 13.12. Thermo Fisher Scientific Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 5. Global Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 6. Global Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 7. Global Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Nanobiotechnology Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 12. North America Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 13. North America Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 14. North America Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 15. North America Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Nanobiotechnology Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 20. United States Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 21. United States Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 22. United States Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 23. United States Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 27. Canada Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 28. Canada Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 29. Canada Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 30. Canada Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 34. Mexico Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 35. Mexico Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 36. Mexico Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 37. Mexico Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 41. Europe Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 42. Europe Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 43. Europe Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 44. Europe Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Nanobiotechnology Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 49. Germany Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 50. Germany Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 51. Germany Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 52. Germany Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 56. France Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 57. France Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 58. France Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 59. France Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 63. Italy Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 64. Italy Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 65. Italy Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 66. Italy Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 70. United Kingdom Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 71. United Kingdom Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 72. United Kingdom Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 73. United Kingdom Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 77. Russia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 78. Russia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 79. Russia Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 80. Russia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 84. Netherlands Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 85. Netherlands Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 86. Netherlands Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 87. Netherlands Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 91. Spain Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 92. Spain Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 93. Spain Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 94. Spain Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 98. Turkey Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 99. Turkey Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 100. Turkey Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 101. Turkey Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 105. Poland Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 106. Poland Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 107. Poland Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 108. Poland Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 112. South America Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 113. South America Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 114. South America Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 115. South America Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Nanobiotechnology Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 120. Brazil Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 121. Brazil Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 122. Brazil Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 123. Brazil Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 127. Argentina Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 128. Argentina Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 129. Argentina Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 130. Argentina Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 134. Asia-Pacific Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 135. Asia-Pacific Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 136. Asia-Pacific Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 137. Asia- Pacific Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Nanobiotechnology Market Share (%), By Country, 2017-2031F
  • Figure 139. India Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 142. India Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 143. India Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 144. India Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 145. India Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 149. China Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 150. China Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 151. China Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 152. China Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 156. Japan Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 157. Japan Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 158. Japan Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 159. Japan Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 163. Australia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 164. Australia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 165. Australia Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 166. Australia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 170. Vietnam Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 171. Vietnam Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 172. Vietnam Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 173. Vietnam Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 177. South Korea Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 178. South Korea Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 179. South Korea Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 180. South Korea Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 184. Indonesia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 185. Indonesia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 186. Indonesia Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 187. Indonesia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 191. Philippines Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 192. Philippines Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 193. Philippines Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 194. Philippines Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 198. Middle East & Africa Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 199. Middle East & Africa Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 200. Middle East & Africa Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 201. Middle East & Africa Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Nanobiotechnology Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 206. Saudi Arabia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 207. Saudi Arabia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 208. Saudi Arabia Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 209. Saudi Arabia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 213. UAE Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 214. UAE Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 215. UAE Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 216. UAE Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Nanobiotechnology Market Share (%), By Type, 2017-2031F
  • Figure 220. South Africa Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
  • Figure 221. South Africa Nanobiotechnology Market Share (%), By Technology, 2017-2031F
  • Figure 222. South Africa Nanobiotechnology Market Share (%), By Application, 2017-2031F
  • Figure 223. South Africa Nanobiotechnology Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Therapeutics Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023